These findings reveal a novel BCR-ABL-independent pathway, AF1q/CD44, involves imatinib resistance in CML, thus representing a potential therapeutic target for imatinib-resistant CML patients. Here, BCR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.